MORAb-003-004 - A Randomized Double-Blind Placebo-Controlled, Phase III Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-Sensitive Ovarian Cancer in First Relapse

Clinical Trial Categories

  • Ovarian Cancer
Contact
Hanjani Institute for Gynecologic Oncology at 215-885-0220

Location

  • Hanjani Institute for Gynecologic Oncology
    The Rosenfeld Cancer Center
    1200 Old York Rd, AMH - 1 Widener
    Abington, PA 19001
    Office: 215-885-0220
    Fax: 215-576-0740